Tuberculosis (TB) is the main reason for preventable loss of life in HIV-positive sufferers, and but typically stays undiagnosed and untreated. Chest x-ray is usually used to help in prognosis, but this presents further challenges as a result of atypical radiographic presentation and radiologist shortages in areas the place co-infection is most typical.
We developed a deep studying algorithm to diagnose TB utilizing scientific data and chest x-ray photographs from 677 HIV-positive sufferers with suspected TB from two hospitals in South Africa.
We then sought to find out whether or not the algorithm might help clinicians within the prognosis of TB in HIV-positive sufferers as a web-based diagnostic assistant.
Use of the algorithm resulted in a modest however statistically important enchancment in clinician accuracy (p = 0.002), growing the imply clinician accuracy from 0.60 (95% CI 0.57, 0.63) with out help to 0.65 (95% CI 0.60, 0.70) with help.
Nonetheless, the accuracy of assisted clinicians was considerably decrease (p < 0.001) than that of the stand-alone algorithm, which had an accuracy of 0.79 (95% CI 0.77, 0.82) on the identical unseen check instances.
These outcomes counsel that deep studying help might enhance clinician accuracy in TB prognosis utilizing chest x-rays, which might be worthwhile in settings with a excessive burden of HIV/TB co-infection. Furthermore, the excessive accuracy of the stand-alone algorithm suggests a possible worth significantly in settings with a shortage of radiological experience.
Tuberculosis Screening in Silica-Uncovered Staff : Creating a Software for Well being Care Suppliers
Each the Occupational Security and Well being Administration and Washington State require security and well being protections for staff uncovered to respirable crystalline silica, together with tuberculosis (TB) screening as a part of occupational medical surveillance.
We describe the creation of a TB screening device for silica-exposed staff receiving regulated medical surveillance examinations in Washington State. The device offers related scientific suggestions to help well being care suppliers and public well being practitioners who select to make use of the device when performing such examinations.
A cross-disciplinary group on the Washington State Division of Labor and Industries created the TB screening device to assist well being care suppliers establish silica-exposed staff who ought to obtain a complete analysis for energetic TB illness and staff who ought to or should obtain testing for latent TB an infection.
The Washington State Grownup Tuberculosis Screening Software for Staff Uncovered to Respirable Crystalline Silica advantages occupational and respiratory clinicians and public well being practitioners by aiding each the individual- and population-level supply of occupational well being and TB screening companies to silica-exposed staff receiving required medical surveillance examinations.
Using thalidomide to deal with kids with tuberculosis meningitis: A assessment
A lot of the morbidity and mortality attributable to tuberculous meningitis (TBM) is mediated by a dysregulated immune response. Efficient host-directed remedy is due to this fact important to enhance survival and scientific outcomes.
At the moment just one host-directed remedy (HDT), corticosteroids, is confirmed to enhance mortality. Nonetheless, there isn’t a proof that corticosteroids scale back morbidity and the mechanism of motion for mortality discount is unsure.
Additional, it has no confirmed profit in HIV co-infected people. One promising host-directed remedy strategy is to limit the immunopathology arising from tumour necrosis issue (TNF)-α extra is by way of TNF-α inhibitors. There are accumulating knowledge on the function of thalidomide, anti-TNF-α monoclonal antibodies (infliximab, adalimumab) and the soluble TNF-α receptor (etanercept) in TBM remedy.
Thalidomide was developed practically seventy years in the past and has been a extremely controversial drug. Delivery defects and poisonous hostile results have restricted its use however an improved understanding of its immunological mechanism of motion counsel that it could have an important function in regulating the damaging host response seen in inflammatory situations similar to TBM.
Observational research at our establishment discovered low dosage adjunctive thalidomide secure in treating tuberculous mass lesions and blindness associated to optochiasmatic arachnoiditis, with good scientific and radiological response.
On this assessment, we focus on attainable mechanisms of motion for thalidomide, primarily based on our clinico-radiologic expertise and autopsy histopathological work. We additionally suggest a rationale for its use within the remedy of sure TBM-related issues.
Co-existence of pulmonary tuberculosis with sarcoidosis
Tuberculosis (TB) and sarcoidosis are multisystem, continual granulomatous ailments. Though characterised by comparable scientific manifestations, these illness entities differ considerably in etiologies and administration.
Sarcoidosis is an immunological dysfunction of unknown etiology, characterised by the presence of noncaseating granulomas within the tissues concerned.
TB is the infectious illness attributable to Mycobacterium tuberculosis, characterised by granulomas with caseous necrosis. It’s uncommon to have each the ailments concomitantly. We current the case of a 38-year-old male with microbiological affirmation of coexistent pulmonary TB and sarcoidosis.
Concomitant disseminated tuberculosis and lepromatous leprosy in a beforehand wholesome male
Tuberculosis (TB) and leprosy are two continual mycobacterial infections attributable to intracellular Gram-positive cardio acid-fast bacilli. Each have extremely variable displays relying on immunological milieu of the host and account for important illness morbidity.
The burden of those age-old infections of humanity nonetheless stays excessive in India. Whatever the similar geographical endemicity of the 2, coinfections are sparsely reported. Certainly, research have revealed an antagonism between them.
Of the few coinfections reported up to now, majority had been recognized over a temporal sequence, with one occurring after the opposite, and most of those had been localized types of TB related to leprosy.
Solely a single case of disseminated TB and lepromatous leprosy has been reported within the medical literature until date. Right here, we report one other uncommon case of disseminated TB and lepromatous leprosy that in the end proved deadly for the affected person. The prognosis of the 2 ailments was made concurrently which is once more rare within the reported literature.
Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Affiliation with Markers of Mycobacterium tuberculosis Burden
There’s a important want for improved pharmacodynamic markers to be used in human tuberculosis (TB) drug trials. Pharmacodynamic monitoring in TB has conventionally used tradition or molecular strategies to enumerate the burden of Mycobacterium tuberculosis organisms in sputum.
A just lately proposed assay referred to as the rRNA synthesis (RS) ratio measures a essentially novel property, how medication affect ongoing bacterial rRNA synthesis. Right here, we evaluated RS ratio as a possible pharmacodynamic monitoring device by testing pretreatment sputa from 38 Ugandan adults with drug-susceptible pulmonary TB.
We quantified the RS ratio in paired pretreatment sputa and evaluated the connection between the RS ratio and microbiologic and molecular markers of M. tuberculosis burden. We discovered that the RS ratio was extremely repeatable and reproducible in sputum samples.
The RS ratio was unbiased of M. tuberculosis burden, confirming that it measures a definite new property. In distinction, markers of M. tuberculosis burden had been strongly related to one another.
These outcomes point out that the RS ratio is repeatable and reproducible and offers a definite kind of data from markers of M. tuberculosis burden.
IMPORTANCE This examine takes a serious subsequent step towards sensible software of a novel pharmacodynamic marker that we imagine can have transformative implications for tuberculosis.
Recombinant other DnaK Mycobacterium Tuberculosis Protein, Untagged, E.coli-10ug |
QP11686-10ug |
EnQuireBio |
10ug |
EUR 241.2 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
MBS6011625-1mg |
MyBiosource |
1(mg |
EUR 1295 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
MBS6011625-5x1mg |
MyBiosource |
5x1mg |
EUR 5675 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
MBS6009340-1mg |
MyBiosource |
1(mg |
EUR 885 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) |
MBS6009340-5x1mg |
MyBiosource |
5x1mg |
EUR 3830 |
MYCOBACTERIUM TUBERCULOSIS |
GWB-FB7063 |
GenWay Biotech |
0.05 mg |
Ask for price |
Mycobacterium tuberculosis |
MBS324183-1mL |
MyBiosource |
1mL |
EUR 320 |
Mycobacterium tuberculosis |
MBS324183-5x1mL |
MyBiosource |
5x1mL |
EUR 1355 |
Mycobacterium tuberculosis |
MBS324184-1mL |
MyBiosource |
1mL |
EUR 335 |
Mycobacterium tuberculosis |
MBS324184-5x1mL |
MyBiosource |
5x1mL |
EUR 1410 |
Mycobacterium tuberculosis |
MBS324185-1mL |
MyBiosource |
1mL |
EUR 355 |
Mycobacterium tuberculosis |
MBS324185-5x1mL |
MyBiosource |
5x1mL |
EUR 1500 |
Mycobacterium tuberculosis |
MBS324186-1mL |
MyBiosource |
1mL |
EUR 335 |
Mycobacterium tuberculosis |
MBS324186-5x1mL |
MyBiosource |
5x1mL |
EUR 1410 |
Mycobacterium tuberculosis |
MBS373078-01mLConcentrate |
MyBiosource |
0.1mL(Concentrate) |
EUR 205 |
Mycobacterium tuberculosis |
MBS373078-05mLConcentrate |
MyBiosource |
0.5mL(Concentrate) |
EUR 310 |
Mycobacterium tuberculosis |
MBS373078-3mLRTU |
MyBiosource |
3mL(RTU) |
EUR 205 |
Mycobacterium tuberculosis |
MBS373078-5ControlSlides |
MyBiosource |
5ControlSlides |
EUR 220 |
Mycobacterium tuberculosis |
MBS373078-7mLRTU |
MyBiosource |
7mL(RTU) |
EUR 310 |
Mycobacterium tuberculosis |
MBS328055-01mg |
MyBiosource |
0.1mg |
EUR 435 |
Mycobacterium tuberculosis |
MBS328055-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1865 |
Mycobacterium tuberculosis |
MBS320211-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mycobacterium tuberculosis |
MBS320211-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1500 |
Mycobacterium tuberculosis |
MBS320212-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mycobacterium tuberculosis |
MBS320212-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1500 |
Mycobacterium tuberculosis |
MBS320213-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mycobacterium tuberculosis |
MBS320213-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1500 |
Mycobacterium tuberculosis |
MBS320214-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mycobacterium tuberculosis |
MBS320214-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1500 |
Mycobacterium tuberculosis |
MBS320334-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mycobacterium tuberculosis |
MBS320334-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1500 |
Mycobacterium tuberculosis |
MBS320336-01mg |
MyBiosource |
0.1mg |
EUR 355 |
Mycobacterium tuberculosis |
MBS320336-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1500 |
Mycobacterium tuberculosis |
MBS6507984-01mg |
MyBiosource |
0.1mg |
EUR 580 |
Mycobacterium tuberculosis |
MBS6507984-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2470 |
Mycobacterium tuberculosis |
PCR-VH201-PCRVH20148D |
Bioingentech |
PCR-VH201-48D |
EUR 230 |
Mycobacterium tuberculosis |
PCR-VH201-PCRVH20196D |
Bioingentech |
PCR-VH201-96D |
EUR 312 |
Mycobacterium tuberculosis |
Oneq-VH201-OneqVH201100D |
Bioingentech |
Oneq-VH201-100D |
EUR 515 |
Mycobacterium tuberculosis |
Oneq-VH201-OneqVH201150D |
Bioingentech |
Oneq-VH201-150D |
EUR 594 |
Mycobacterium tuberculosis |
Oneq-VH201-OneqVH20150D |
Bioingentech |
Oneq-VH201-50D |
EUR 413 |
Mycobacterium tuberculosis (M. tuberculosis) Antibody |
abx415707-1ml |
Abbexa |
1 ml |
EUR 727.2 |
|
Mycobacterium tuberculosis (M. tuberculosis) Antibody |
abx415707-200l |
Abbexa |
200 µl |
EUR 537.5 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
MBS6129466-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
MBS6129466-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
MBS6129467-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE) |
MBS6129467-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
MBS6126370-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
MBS6126370-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
MBS6126371-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP) |
MBS6126371-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
MBS6128846-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
MBS6128846-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
MBS6128847-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP) |
MBS6128847-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
MBS6126990-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
MBS6126990-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
MBS6126991-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC) |
MBS6126991-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
MBS6128225-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
MBS6128225-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
MBS6128226-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC) |
MBS6128226-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
MBS6127611-01mL |
MyBiosource |
0.1(mL |
EUR 1240 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
MBS6127611-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5430 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
MBS6127612-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin) |
MBS6127612-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Recombinant purified Mycobacterium Tuberculosis Heat Shock Protein 70 (hsp70/Dnak/ML2496) |
RP-628 |
Alpha Diagnostics |
10 ug |
EUR 343.2 |
Mycobacterium tuberculosis (AP) |
MBS6450376-01mL |
MyBiosource |
0.1mL |
EUR 700 |
Mycobacterium tuberculosis (AP) |
MBS6450376-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2995 |
Mycobacterium tuberculosis (PE) |
MBS6450386-01mL |
MyBiosource |
0.1mL |
EUR 700 |
Mycobacterium tuberculosis (PE) |
MBS6450386-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2995 |
Mycobacterium tuberculosis (APC) |
MBS6450377-01mL |
MyBiosource |
0.1mL |
EUR 700 |
Mycobacterium tuberculosis (APC) |
MBS6450377-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2995 |
Mycobacterium tuberculosis (HRP) |
MBS6450380-01mL |
MyBiosource |
0.1mL |
EUR 700 |
Mycobacterium tuberculosis (HRP) |
MBS6450380-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2995 |
Mycobacterium tuberculosis Genomic DNA |
MBT107-250R |
EWC Diagnostics |
1 unit |
EUR 119.62 |
Description: Mycobacterium tuberculosis Genomic DNA |
Mycobacterium tuberculosis, HSPX |
MBS633358-1mL |
MyBiosource |
1mL |
EUR 555 |
Mycobacterium tuberculosis, HSPX |
MBS633358-5x1mL |
MyBiosource |
5x1mL |
EUR 2355 |
Mycobacterium tuberculosis, HSPX |
MBS632079-1mL |
MyBiosource |
1mL |
EUR 555 |
Mycobacterium tuberculosis, HSPX |
MBS632079-5x1mL |
MyBiosource |
5x1mL |
EUR 2355 |
Mycobacterium tuberculosis, 38kD |
MBS631535-1mg |
MyBiosource |
1mg |
EUR 885 |
Mycobacterium tuberculosis, 38kD |
MBS631535-5x1mg |
MyBiosource |
5x1mg |
EUR 3830 |
Mycobacterium tuberculosis (FITC) |
MBS6450379-01mL |
MyBiosource |
0.1mL |
EUR 700 |
Mycobacterium tuberculosis (FITC) |
MBS6450379-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2995 |
Mycobacterium tuberculosis, 38kD |
MBS609237-1mg |
MyBiosource |
1mg |
EUR 855 |
Mycobacterium tuberculosis, 38kD |
MBS609237-5x1mg |
MyBiosource |
5x1mg |
EUR 3700 |
Mycobacterium tuberculosis, 38kD |
MBS609285-1mg |
MyBiosource |
1mg |
EUR 925 |
Mycobacterium tuberculosis, 38kD |
MBS609285-5x1mg |
MyBiosource |
5x1mg |
EUR 4015 |
Mycobacterium tuberculosis 38kDa |
GWB-67DB4A |
GenWay Biotech |
5 mg |
Ask for price |
Mycobacterium tuberculosis 16kDa |
GWB-7F0CCF |
GenWay Biotech |
5 mg |
Ask for price |
Mycobacterium tuberculosis CFP10 |
MBS601269-01mg |
MyBiosource |
0.1mg |
EUR 325 |
Mycobacterium tuberculosis CFP10 |
MBS601269-1mg |
MyBiosource |
1mg |
EUR 1080 |
Mycobacterium tuberculosis CFP10 |
MBS601269-5x1mg |
MyBiosource |
5x1mg |
EUR 4700 |
Mycobacterium tuberculosis CFP10 |
MBS602176-1mg |
MyBiosource |
1mg |
EUR 1080 |
Mycobacterium tuberculosis CFP10 |
MBS602176-5x1mg |
MyBiosource |
5x1mg |
EUR 4700 |
Mycobacterium tuberculosis ESAT6 |
MBS6506783-01mg |
MyBiosource |
0.1mg |
EUR 760 |
Mycobacterium tuberculosis ESAT6 |
MBS6506783-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3265 |
Mycobacterium tuberculosis (Biotin) |
MBS6450378-01mL |
MyBiosource |
0.1mL |
EUR 700 |
Mycobacterium tuberculosis (Biotin) |
MBS6450378-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2995 |
Mycobacterium tuberculosis Antibody |
abx022066-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
Mycobacterium tuberculosis Antibody |
abx022066-400l |
Abbexa |
400 µl |
Ask for price |
Mycobacterium tuberculosis Antibody |
abx022066-80l |
Abbexa |
80 µl |
EUR 1200 |
Mycobacterium tuberculosis Antibody |
abx022067-1mg |
Abbexa |
1 mg |
EUR 1296 |
|
Mycobacterium tuberculosis Antibody |
abx022067-400l |
Abbexa |
400 µl |
Ask for price |
Mycobacterium tuberculosis Antibody |
abx022067-80l |
Abbexa |
80 µl |
EUR 1287.5 |
Mycobacterium tuberculosis Antibody |
abx022073-1mg |
Abbexa |
1 mg |
EUR 1296 |
|
Mycobacterium tuberculosis Antibody |
abx022073-400l |
Abbexa |
400 µl |
Ask for price |
Mycobacterium tuberculosis Antibody |
abx022073-80l |
Abbexa |
80 µl |
EUR 1287.5 |
Mycobacterium tuberculosis Antibody |
abx022087-1mg |
Abbexa |
1 mg |
EUR 994.8 |
|
Mycobacterium tuberculosis Antibody |
abx022088-1mg |
Abbexa |
1 mg |
EUR 994.8 |
|
Mycobacterium tuberculosis Antibody |
abx022089-1mg |
Abbexa |
1 mg |
EUR 944.4 |
|
Mycobacterium tuberculosis Antibody |
abx022090-1mg |
Abbexa |
1 mg |
EUR 944.4 |
|
Mycobacterium tuberculosis Antibody |
abx023092-1ml |
Abbexa |
1 ml |
EUR 718.8 |
|
Mycobacterium tuberculosis Antibody |
abx023092-400l |
Abbexa |
400 µl |
Ask for price |
Mycobacterium tuberculosis Antibody |
abx023092-80l |
Abbexa |
80 µl |
EUR 1012.5 |
Mycobacterium tuberculosis antibody |
20-MR50 |
Fitzgerald |
1 mg |
EUR 110 |
|
Description: Rabbit polyclonal Mycobacterium tuberculosis antibody |
Mycobacterium tuberculosis Antibody |
GWB-52959A |
GenWay Biotech |
1 ml |
Ask for price |
|
Mycobacterium tuberculosis Antibody |
GWB-AE5BA3 |
GenWay Biotech |
1 ml |
Ask for price |
Mycobacterium tuberculosis, Antibody |
GWB-1A49B9 |
GenWay Biotech |
0.1 mg Purified |
Ask for price |
|
Mycobacterium tuberculosis Antibody |
GWB-613CF2 |
GenWay Biotech |
1 ml |
Ask for price |
Mycobacterium tuberculosis Antibody |
GWB-37A518 |
GenWay Biotech |
0.5 ml |
Ask for price |
|
Mycobacterium Tuberculosis Antibody |
GWB-EF714E |
GenWay Biotech |
1 ml |
Ask for price |
Mycobacterium tuberculosis Antibody |
GWB-CAE926 |
GenWay Biotech |
1 ml |
Ask for price |
Mycobacterium tuberculosis Antibody |
MBS568506-05mL |
MyBiosource |
0.5mL |
EUR 305 |
Mycobacterium tuberculosis Antibody |
MBS568506-5x05mL |
MyBiosource |
5x0.5mL |
EUR 1180 |
Mycobacterium tuberculosis antibody |
MBS534825-1mg |
MyBiosource |
1mg |
EUR 240 |
Mycobacterium tuberculosis, 38kD (PE) |
MBS6129472-01mL |
MyBiosource |
0.1(mL |
EUR 1135 |
Mycobacterium tuberculosis, 38kD (PE) |
MBS6129472-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4960 |
Mycobacterium tuberculosis, 38kD (PE) |
MBS6129473-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis, 38kD (PE) |
MBS6129473-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis, 38kD (PE) |
MBS6129474-01mL |
MyBiosource |
0.1(mL |
EUR 1070 |
Mycobacterium tuberculosis, 38kD (PE) |
MBS6129474-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4670 |
Mycobacterium tuberculosis, 38kD (AP) |
MBS6126376-01mL |
MyBiosource |
0.1(mL |
EUR 1135 |
Mycobacterium tuberculosis, 38kD (AP) |
MBS6126376-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4960 |
Mycobacterium tuberculosis, 38kD (AP) |
MBS6126377-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis, 38kD (AP) |
MBS6126377-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis, 38kD (AP) |
MBS6126378-01mL |
MyBiosource |
0.1(mL |
EUR 1070 |
Mycobacterium tuberculosis, 38kD (AP) |
MBS6126378-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4670 |
Mycobacterium tuberculosis PCR kit |
PCR-VH201-48D |
Bioingentech |
50T |
EUR 543.6 |
Mycobacterium tuberculosis PCR kit |
PCR-VH201-96D |
Bioingentech |
100T |
EUR 686.4 |
Insta NX® Mycobacterium Tuberculosis DNA |
MBIN019-12PR |
EWC Diagnostics |
1 unit |
EUR 71.73 |
Description: Insta NX® Mycobacterium Tuberculosis DNA |
Mycobacterium Tuberculosis-IN-2 |
HY-157431 |
MedChemExpress |
Get quote |
Ask for price |
Description: Mycobacterium Tuberculosis-IN-2 (Compound 29) is a bacterial inhibitor that effectively inhibits Mycobacterium Tuberculosis. Mycobacterium Tuberculosis-IN-2 can be used in tuberculosis research[1]. |
Mycobacterium tuberculosis, 38kD (HRP) |
MBS6128852-01mL |
MyBiosource |
0.1(mL |
EUR 1135 |
Mycobacterium tuberculosis, 38kD (HRP) |
MBS6128852-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4960 |
Mycobacterium tuberculosis, 38kD (HRP) |
MBS6128853-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis, 38kD (HRP) |
MBS6128853-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis, 38kD (HRP) |
MBS6128854-01mL |
MyBiosource |
0.1(mL |
EUR 1070 |
Mycobacterium tuberculosis, 38kD (HRP) |
MBS6128854-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4670 |
Mycobacterium tuberculosis CFP10 (PE) |
MBS6129468-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (PE) |
MBS6129468-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis CFP10 (PE) |
MBS6129469-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (PE) |
MBS6129469-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis, 38kD (APC) |
MBS6126996-01mL |
MyBiosource |
0.1(mL |
EUR 1135 |
Mycobacterium tuberculosis, 38kD (APC) |
MBS6126996-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4960 |
Mycobacterium tuberculosis, 38kD (APC) |
MBS6126997-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis, 38kD (APC) |
MBS6126997-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis, 38kD (APC) |
MBS6126998-01mL |
MyBiosource |
0.1(mL |
EUR 1070 |
Mycobacterium tuberculosis, 38kD (APC) |
MBS6126998-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4670 |
Mycobacterium tuberculosis CFP10 (AP) |
MBS6126372-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (AP) |
MBS6126372-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis CFP10 (AP) |
MBS6126373-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (AP) |
MBS6126373-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
HiPurA® Mycobacterium Tuberculosis DNA P |
MB545-20PR |
EWC Diagnostics |
1 unit |
EUR 45.83 |
Description: HiPurA® Mycobacterium Tuberculosis DNA P |
HiPurA® Mycobacterium Tuberculosis DNA P |
MB545-250PR |
EWC Diagnostics |
1 unit |
EUR 415.6 |
Description: HiPurA® Mycobacterium Tuberculosis DNA P |
HiPurA® Mycobacterium Tuberculosis DNA P |
MB545-50PR |
EWC Diagnostics |
1 unit |
EUR 91.58 |
Description: HiPurA® Mycobacterium Tuberculosis DNA P |
Mycobacterium tuberculosis IgA ELISA |
GWB-20EB9D |
GenWay Biotech |
ELISA_Kits |
Ask for price |
|
Mycobacterium tuberculosis IgM ELISA |
GWB-784B40 |
GenWay Biotech |
ELISA_Kits |
Ask for price |
Mycobacterium tuberculosis IgG ELISA |
GWB-FFE4D4 |
GenWay Biotech |
ELISA_Kits |
Ask for price |
Mycobacterium tuberculosis CFP10 (HRP) |
MBS6128848-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (HRP) |
MBS6128848-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis CFP10 (HRP) |
MBS6128849-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (HRP) |
MBS6128849-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis CFP10 (APC) |
MBS6126992-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (APC) |
MBS6126992-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis CFP10 (APC) |
MBS6126993-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (APC) |
MBS6126993-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis, 38kD (FITC) |
MBS6128231-01mL |
MyBiosource |
0.1(mL |
EUR 1135 |
Mycobacterium tuberculosis, 38kD (FITC) |
MBS6128231-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4960 |
Mycobacterium tuberculosis, 38kD (FITC) |
MBS6128232-01mL |
MyBiosource |
0.1(mL |
EUR 1095 |
Mycobacterium tuberculosis, 38kD (FITC) |
MBS6128232-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4775 |
Mycobacterium tuberculosis, 38kD (FITC) |
MBS6128233-01mL |
MyBiosource |
0.1(mL |
EUR 1070 |
Mycobacterium tuberculosis, 38kD (FITC) |
MBS6128233-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4670 |
Mycobacterium tuberculosis CFP10 (FITC) |
MBS6128227-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (FITC) |
MBS6128227-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis CFP10 (FITC) |
MBS6128228-01mL |
MyBiosource |
0.1(mL |
EUR 1285 |
Mycobacterium tuberculosis CFP10 (FITC) |
MBS6128228-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5640 |
Mycobacterium tuberculosis (TB) Antibody |
MBS569356-1mg |
MyBiosource |
1mg |
EUR 655 |
Mycobacterium tuberculosis (TB) Antibody |
MBS569356-5x1mg |
MyBiosource |
5x1mg |
EUR 2760 |
This text follows our latest report in Nature Communications that an assay referred to as the rRNA synthesis (RS) ratio signifies the treatment-shortening of medication and regimens.
Distinct from conventional measures of bacterial burden, the RS ratio measures a essentially novel property, how medication affect ongoing bacterial rRNA synthesis.